| # | Title | Journal | Year | Citations |
|---|
| 1 | FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 | European Journal of Nuclear Medicine and Molecular Imaging | 2015 | 2,188 |
| 2 | FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 | European Journal of Nuclear Medicine and Molecular Imaging | 2010 | 1,147 |
| 3 | Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use | European Journal of Nuclear Medicine and Molecular Imaging | 2000 | 913 |
| 4 | The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer | European Journal of Nuclear Medicine and Molecular Imaging | 2015 | 866 |
| 5 | Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer | European Journal of Nuclear Medicine and Molecular Imaging | 2014 | 817 |
| 6 | PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions | European Journal of Nuclear Medicine and Molecular Imaging | 2013 | 773 |
| 7 | Brain glucose metabolism in the early and specific diagnosis of Alzheimer?s disease | European Journal of Nuclear Medicine and Molecular Imaging | 2005 | 744 |
| 8 | The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours | European Journal of Nuclear Medicine and Molecular Imaging | 2013 | 633 |
| 9 | Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2 | European Journal of Nuclear Medicine and Molecular Imaging | 2020 | 612 |
| 10 | Guidelines for radioiodine therapy of differentiated thyroid cancer | European Journal of Nuclear Medicine and Molecular Imaging | 2008 | 593 |
| 11 | 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0 | European Journal of Nuclear Medicine and Molecular Imaging | 2017 | 589 |
| 12 | Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study | European Journal of Nuclear Medicine and Molecular Imaging | 2003 | 510 |
| 13 | Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting | European Journal of Nuclear Medicine and Molecular Imaging | 2003 | 492 |
| 14 | Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data | European Journal of Nuclear Medicine and Molecular Imaging | 2001 | 470 |
| 15 | EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2 | European Journal of Nuclear Medicine and Molecular Imaging | 2009 | 469 |
| 16 | EANM/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology | European Journal of Nuclear Medicine and Molecular Imaging | 2005 | 467 |
| 17 | Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours | European Journal of Nuclear Medicine and Molecular Imaging | 2007 | 467 |
| 18 | Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region | European Journal of Nuclear Medicine and Molecular Imaging | 2002 | 460 |
| 19 | Prospective comparison of 18 F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer | European Journal of Nuclear Medicine and Molecular Imaging | 1998 | 427 |
| 20 | Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients | European Journal of Nuclear Medicine and Molecular Imaging | 2017 | 425 |
| 21 | Myocardial perfusion scintigraphy: the evidence | European Journal of Nuclear Medicine and Molecular Imaging | 2004 | 424 |
| 22 | F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients | European Journal of Nuclear Medicine and Molecular Imaging | 2017 | 421 |
| 23 | Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT | European Journal of Nuclear Medicine and Molecular Imaging | 2009 | 419 |
| 24 | FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer’s disease | European Journal of Nuclear Medicine and Molecular Imaging | 2009 | 409 |
| 25 | Early diagnosis and follow-up of aortitis with [18F]FDG PET and MRI | European Journal of Nuclear Medicine and Molecular Imaging | 2003 | 396 |
| 26 | Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis | European Journal of Nuclear Medicine and Molecular Imaging | 2013 | 395 |
| 27 | Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE | European Journal of Nuclear Medicine and Molecular Imaging | 2010 | 394 |
| 28 | PET attenuation coefficients from CT images: experimental evaluation of the transformation of CT into PET 511-keV attenuation coefficients | European Journal of Nuclear Medicine and Molecular Imaging | 2002 | 379 |
| 29 | Characterization of PET/CT images using texture analysis: the past, the present… any future? | European Journal of Nuclear Medicine and Molecular Imaging | 2017 | 376 |
| 30 | A gradient-based method for segmenting FDG-PET images: methodology and validation | European Journal of Nuclear Medicine and Molecular Imaging | 2007 | 373 |
| 31 | Quantification of myocardial blood flow with 82Rb dynamic PET imaging | European Journal of Nuclear Medicine and Molecular Imaging | 2007 | 373 |
| 32 | Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers | European Journal of Nuclear Medicine and Molecular Imaging | 2008 | 359 |
| 33 | In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM | European Journal of Nuclear Medicine and Molecular Imaging | 2003 | 358 |
| 34 | Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors | European Journal of Nuclear Medicine and Molecular Imaging | 2015 | 357 |
| 35 | Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate | European Journal of Nuclear Medicine and Molecular Imaging | 2003 | 356 |
| 36 | The detection rate of [11C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer | European Journal of Nuclear Medicine and Molecular Imaging | 2008 | 355 |
| 37 | O -(2-[ 18 F]Fluoroethyl)- l -tyrosine and l -[methyl- 11 C]methionine uptake in brain tumours: initial results of a comparative study | European Journal of Nuclear Medicine and Molecular Imaging | 2000 | 353 |
| 38 | Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors | European Journal of Nuclear Medicine and Molecular Imaging | 2008 | 353 |
| 39 | Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study | European Journal of Nuclear Medicine and Molecular Imaging | 2011 | 349 |
| 40 | Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours | European Journal of Nuclear Medicine and Molecular Imaging | 1997 | 348 |
| 41 | Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0 | European Journal of Nuclear Medicine and Molecular Imaging | 2019 | 348 |
| 42 | Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer | European Journal of Nuclear Medicine and Molecular Imaging | 2020 | 348 |
| 43 | Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? | European Journal of Nuclear Medicine and Molecular Imaging | 2007 | 347 |
| 44 | A review on the clinical uses of SPECT/CT | European Journal of Nuclear Medicine and Molecular Imaging | 2010 | 347 |
| 45 | Radioimmunotherapy with alpha-emitting nuclides | European Journal of Nuclear Medicine and Molecular Imaging | 1998 | 343 |
| 46 | The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials | European Journal of Nuclear Medicine and Molecular Imaging | 2008 | 343 |
| 47 | Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer | European Journal of Nuclear Medicine and Molecular Imaging | 2011 | 337 |
| 48 | The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease | European Journal of Nuclear Medicine and Molecular Imaging | 2005 | 334 |
| 49 | FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC | European Journal of Nuclear Medicine and Molecular Imaging | 2018 | 332 |
| 50 | EANM guidelines for ventilation/perfusion scintigraphy | European Journal of Nuclear Medicine and Molecular Imaging | 2009 | 328 |
